BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+3.30 (+11.79%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close28.00
Bid29.75 x 1100
Ask31.60 x 900
Day's Range28.65 - 31.30
52 Week Range12.52 - 31.30
Avg. Volume289,023
Market Cap6.8B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Press Releases
  • GlobeNewswire

    BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

    Successfully transferred IND for BNT321 to BioNTech. Initiated a first-in-human global Phase 1/2a trial in collaboration with Genmab for GEN1042 (BNT312), a bispecific antibody targeting CD40 and 4-1BB for the treatment of multiple solid tumors. Entered into a clinical trial supply agreement with Regeneron to supply cemiplimab for use in combination with BioNTech’s BNT112 in a first-in-human Phase 1/2 trial of FixVac in advanced prostate cancer and received approval of clinical trial applications (CTAs) in various European countries to support the initiation of this trial.

  • GlobeNewswire

    BioNTech to Report Third Quarter 2019 Financial Results and Operational Progress on November 14, 2019

    MAINZ, Germany, Nov. 07, 2019 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for.

  • Business Wire

    BioNTech Announces Pricing of Initial Public Offering

    BioNTech SE , a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced the pricing of its initial public offering of 10,000,000 American Depositary Shares representing 10,000,000 ordinary shares at a public offering price of $15.00 per ADS, for gross proceeds of $150,000,000.